Merck & Co (MRK) AGM 2025 summary

Opening remarks and agenda

• Meeting opened virtually, ensuring consistent experience for all shareholders.

• Quorum confirmed with over 85% of votes represented.

• Agenda included executive updates, financial review, shareholder proposals, and Q&A.

Financial performance review

• Achieved 10% top-line growth in 2024, with sales reaching $64.2 billion and non-GAAP EPS of $7.65.

• Absorbed significant decline in Gardasil demand in China, but overall business remains healthy.

• Pipeline is highly diversified, with nearly 20 potential blockbuster products on the horizon.

Board and executive committee updates

• Board consists of experienced leaders; all 13 director nominees elected by majority vote.

• PricewaterhouseCoopers LLP ratified as independent auditor for 2025.